Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study

医学 生活质量(医疗保健) 安慰剂 物理疗法 内科学 临床试验 临床终点 肥厚性心肌病 不利影响 体力活动 随机对照试验 前瞻性队列研究 梗阻性心肌病 健康相关生活质量 心肌病 梗阻性肥厚性心肌病
作者
Zhuang Tian,Xiaoyan Li,Liwen Li,Qing Zhang,Jianan Wang,Y Q Shi,D Q Peng,Wei Ma,Ping Yang,Xiang Cheng,Wei Jin,Fang Wang,Arteid Memaj,Yimeng Xie,Beth Pan,Victoria Florea,Jing Zheng,Yue Zhong,S Y Zhang
出处
期刊:Cardiology and Therapy [Adis, Springer Healthcare]
卷期号:15 (2): 185-200
标识
DOI:10.1007/s40119-026-00449-5
摘要

INTRODUCTION: Improvement of symptoms, physical function, and quality of life is one treatment goal for patients with obstructive hypertrophic cardiomyopathy (HCM). Mavacamten improved left-ventricular outflow tract gradients in Chinese patients with obstructive HCM in the EXPLORER-CN trial. We report here a detailed analysis of patient-reported health status per the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ-23) in Chinese patients after 78 weeks of mavacamten. METHODS: Patients who completed the double-blind, placebo-controlled (DBPC) period of EXPLORER-CN with no active safety concerns could enter a long-term extension (LTE) period to receive mavacamten for 48 weeks at either the 30-week dose (mavacamten-mavacamten group) or a once-daily starting dose of 2.5 mg (subsequently adjusted via pharmacodynamics-based dose titration: placebo-mavacamten group). Health status endpoints included KCCQ-23 clinical summary score (CSS), overall symptom score (OSS), total symptom score (TSS), physical limitations score, and quality-of-life scores through week 78. Week 78 endpoint analyses were descriptive. RESULTS: In the DBPC period, 54 patients received mavacamten and 27 received placebo; of these, 54 and 25, respectively, entered the LTE period. KCCQ-23 CSS, OSS, and TSS improved with mavacamten and worsened with placebo during the DBPC period (mean change baseline to week 30: 5.7, 6.4, and 8.1, respectively [mavacamten-mavacamten group] and - 5.4, - 4.3, and - 4.8, respectively [placebo-mavacamten group]). CSS, OSS, and TSS continued to improve in the mavacamten-mavacamten group during the LTE period (mean change baseline to week 78: 7.1, 8.2, and 10.0, respectively). Scores improved in the placebo-mavacamten group after switching to mavacamten (mean change week 30 to week 78: 7.3, 9.5, and 5.7, respectively). Similar improvements in KCCQ-23 physical limitations and quality-of-life scores with mavacamten were observed throughout both study periods. CONCLUSIONS: Long-term mavacamten treatment for up to 78 weeks led to sustained improvements in patient-reported health status, supporting long-term treatment with mavacamten for Chinese patients with symptomatic obstructive HCM. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT05174416.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
科研民工完成签到,获得积分10
2秒前
2秒前
拼搏夜梅发布了新的文献求助20
3秒前
aa发布了新的文献求助10
4秒前
Fred Guan的应助被wmc666采纳,获得10
4秒前
科研通AI6.3的应助被wmc666采纳,获得10
4秒前
5秒前
5秒前
5秒前
5秒前
江花朝完成签到,获得积分10
5秒前
5秒前
6秒前
6秒前
酷波er的应助被晚梦采纳,获得10
6秒前
lunhui6453发布了新的文献求助10
6秒前
6秒前
wanci的应助被匆匆采纳,获得10
7秒前
cdercder的应助被wuda采纳,获得10
7秒前
源源完成签到,获得积分10
8秒前
鹿呦完成签到 ,获得积分10
8秒前
8秒前
8秒前
8秒前
9秒前
旧林完成签到,获得积分10
9秒前
trx发布了新的文献求助10
9秒前
木木夕完成签到,获得积分10
9秒前
10秒前
10秒前
风吹水响发布了新的文献求助10
10秒前
风吹水响发布了新的文献求助10
10秒前
无极微光的应助被Flora采纳,获得20
11秒前
洁净丹云发布了新的文献求助30
11秒前
希望天下0贩的0的应助被justgold采纳,获得10
12秒前
13秒前
正途发布了新的文献求助10
13秒前
7788完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192519
求助须知:如何正确求助?哪些是违规求助? 9579028
关于积分的说明 21863207
捐赠科研通 7792025
什么是DOI,文献DOI怎么找? 3436955
关于科研通互助平台的介绍 2560622
邀请新用户注册赠送积分活动 2483832